Acumen Pharmaceuticals (ABOS) Set to Release Earnings on Monday

Key Points

• Acumen Pharmaceuticals is expected to report Q3 2026 results before the market opens Monday, October 26. Analysts project a loss of $0.43 per share, with the earnings call scheduled for 8:00 a.m. ET.
• The company previously reported a $0.45-per-share loss, missing consensus expectations of a $0.36 loss. Analysts anticipate full-year and next-year losses of $1.60 and $1.67 per share, respectively.
• ABOS shares opened at $2.02, versus a 12-month range of $1.50 to $3.60. Despite mixed analyst opinions, the stock carries a “Moderate Buy” consensus rating and a $7.00 average price target.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Monday, October 26th. Analysts expect Acumen Pharmaceuticals to announce earnings of ($0.43) per share for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, October 26, 2026 at 8:00 AM ET.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.09). On average, analysts expect Acumen Pharmaceuticals to post ($1.60) EPS for the current fiscal year and ($1.67) EPS for the next fiscal year.

Acumen Pharmaceuticals Price Performance

Shares of NASDAQ ABOS opened at $2.02 on Wednesday. Acumen Pharmaceuticals has a twelve month low of $1.50 and a twelve month high of $3.60. The firm has a market cap of $145.72 million, a P/E ratio of -1.24 and a beta of 0.33. The company has a 50 day moving average of $2.55 and a 200 day moving average of $2.48. The company has a quick ratio of 2.47, a current ratio of 2.47 and a debt-to-equity ratio of 0.21.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Acumen Pharmaceuticals in a report on Thursday, September 17th. BTIG Research restated a "buy" rating and issued a $8.00 price target on shares of Acumen Pharmaceuticals in a research note on Wednesday, September 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Acumen Pharmaceuticals in a report on Friday, October 2nd. Wall Street Zen downgraded Acumen Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Saturday. Finally, Citigroup increased their price objective on Acumen Pharmaceuticals from $4.00 to $5.00 and gave the company a "buy" rating in a research report on Tuesday, September 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $7.00.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease. The company's research is based on the amyloid-beta oligomer hypothesis, which holds that soluble forms of amyloid-beta may contribute to the synaptic dysfunction and neurodegeneration associated with the disease.

Acumen's lead product candidate is sabirnetug, also known as ACU193, an investigational humanized monoclonal antibody designed to selectively target toxic soluble amyloid-beta oligomers while seeking to avoid binding to monomeric amyloid-beta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.